306 related articles for article (PubMed ID: 27043847)
1. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
5. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
6. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
8. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
11. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
16. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]